Chemomab Therapeutics
CMMB
15 hedge funds and large institutions have $35.9M invested in Chemomab Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
74% more capital inflows, than outflows
Capital inflows: $4.51M | Capital outflows: $2.6M
25% more funds holding
Funds holding: 12 → 15 (+3)
1.37% more ownership
Funds ownership: 27.07% → 28.43% (+1.4%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$2.75M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$834K |
| 3 |
State Street
Boston,
Massachusetts
|
+$464K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$209K |
| 5 |
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.21M |
| 2 |
Marshall Wace North America
New York
|
-$837K |
| 3 |
Virtu Financial
New York
|
-$251K |
| 4 |
Boothbay Fund Management
New York
|
-$171K |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$80.2K |
CMMB Hedge Fund Activity: Q3 2021 in Review
15 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2021, worth a combined $35.9M — down 39% from $58.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CMMB positions and 4 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $2.75M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.21M sold.
- 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2021, up from 12 in Q2 2021.
- Funds reported $35.9M of Chemomab Therapeutics stock for Q3 2021, down 39% quarter-over-quarter.
- 7 funds opened new Chemomab Therapeutics positions in Q3 2021 and 4 closed out, a net change of +3 holders.
- The largest Chemomab Therapeutics buyer in Q3 2021 was ARK Investment Management, an estimated $2.75M added.
- The largest Chemomab Therapeutics seller in Q3 2021 was Marshall Wace, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2021.